title: Does aprotinin preserve platelets in children with acyanogenic congenital heart disease undergone surgery with cardiopulmonary bypass?
abstract: OBJECTIVE
  Evaluation of the hemostatic and platelets effects in children with acyanogenic congenital heart disease undergone on-pump surgery who received aprotinin.
  
  
  METHODS
  A prospective randomized study was performed on children aged 30 days to 4 years who had undergone correction of acyanogenic congenital heart disease using cardiopulmonary bypass (CPB) and were divided into two groups: Control (n=9) and Aprotinin (n=10). In the Aprotinin Group the drug was administered before and during CPB and the hemostatic dysfunction was analyzed by clinical and biochemical markers. Differences were considered to be significant when P<0.05.
  
  
  RESULTS
  The groups were similar regarding demographic and intraoperative variables, except for a greater hemodilution in the Aprotinin Group. The drug presented no benefit regarding time of mechanical pulmonary ventilation, stay in the postoperative intensive care unit and hospital, or regarding the use of inotropic drugs and renal function. Platelet concentration was preserved with the use of Aprotinin, whereas thrombocytopenia occurred in the Control Group since the initiation of CPB. Blood loss was similar for both groups. There were no complications with the use of Aprotinin.
  
  
  CONCLUSIONS
  Aprotinin quantitatively preserved the blood platelets in children with acyanogenic congenital heart disease.
authors.affiliation: Thoracic and Cardiovascular Surgery Discipline of Surgery and Anatomy Department at Clinics Hospital of Ribeirão Preto Medical School - University of São Paulo, Brazil. cesarmonica@directnet.com.br
authors.forename: Cesar Augusto
authors.initials: CA
authors.lastname: Ferreira
authors.forename: Walter Villela de Andrade
authors.initials: WV
authors.lastname: Vicente
authors.forename: Paulo Roberto Barbosa
authors.initials: PR
authors.lastname: Evora
authors.forename: Alfredo José
authors.initials: AJ
authors.lastname: Rodrigues
authors.forename: Jyrson Guilherme
authors.initials: JG
authors.lastname: Klamt
authors.forename: Ana Paula de Carvalho Panzeli
authors.initials: AP
authors.lastname: Carlotti
authors.forename: Fábio
authors.initials: F
authors.lastname: Carmona
authors.forename: Paulo Henrique
authors.initials: PH
authors.lastname: Manso
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D007611:Aprotinin / Q000009:adverse effects / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects*; D002315:Cardiopulmonary Bypass; D002675:Child, Preschool; D005260:Female; D006330:Heart Defects, Congenital / Q000601:surgery*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D007611:Aprotinin